Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aplaviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplaviroc SCHEMBL15531476 | 1.00 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL5345222 | 1.00 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL4577096 | 1.00 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL6190417 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL5578746 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186236 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL5578741 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL6186135 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL4821965 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 | |
| Aplaviroc SCHEMBL5346716 | 0.99 | CCR5 (1.00) | CCR5CXCR4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329809-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-06 | — | — | US | claimed |
| EP-2771484-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | Galderma Research & Development (FR) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060865-A1 | NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | claimed |
| US-20250090637-A1 | METHODS OF INHIBITING CEREBRAL INFLAMMATION | UNIVERSITÉ DE GENÈVE (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4264280-A1 | METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19 | IncellDx, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3813869-B1 | CCR5 INHIBITOR FOR USE IN TREATING A NEUROINFLAMMATORY DISORDER THAT INVOLVES CEREBRAL INFLAMMATION | UNIV GENEVE (CH) | 2023-10-18 | — | — | EP | disclosed |
| US-20230172912-A1 | COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION | HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2022140299-A1 | METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19 | INCELLDX, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20210205412-A1 | METHODS OF INHIBITING CEREBRAL INFLAMMATION | UNIVERSITÉ DE GENÈVE (CH) | 2021-07-08 | — | — | US | disclosed |
| EP-3818171-A1 | METHODS FOR DETECTING CANCER-RELATED CELL POPULATIONS, SCREENING FOR METASTATIC CANCER AND TREATMENTS THEREOF | IncellDx, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20080039428-A1 | Antiretroviral combination therapy | PANACOS PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | CCR5 7/4885CXCR4 24/4885CYP2C9 4784/4885 |
| US-20230172912-A1 | COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION | CCR5, CXCR3, CCL5 | CCR5 1/4885CXCR4 19/4885CYP2C9 859/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | CCR5 8/4885CXCR4 26/4885CYP2C9 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.